Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications

Kolberg, Hans-Christian; Tomasevic, Zoran M; Demetriou, Georgia S; von, Minckwitz Gunter; Fujiwara, Yasuhiro; Ponomarova, O; Tesch, Hans; Santi, Patricia Xavier; Hanes, Vladimir

Rezultati

eNauka > Rezultati > Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications

Naziv:	Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications
Autori:	Kolberg, Hans-Christian; Tomasevic, Zoran M; Demetriou, Georgia S; von, Minckwitz Gunter; Fujiwara, Yasuhiro; Ponomarova, O; Tesch, Hans; Santi, Patricia Xavier; Hanes, Vladimir
Godina:	2018
Publikacija:	EUROPEAN JOURNAL OF CANCER
ISSN:	0959-8049 European Journal of Cancer / EJC Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 92 str. S103-S104
WoS-ID:	000429103100279
URI:	https://enauka.gov.rs/handle/123456789/818498
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

2
WEB OF SCIENCE^TM

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.